Related Experiment Video
Updated: Jul 21, 2026
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Preclinical Stroke Research and Translational Failure: A Bird's Eye View on Preventable Variables
Devendra Singh1, Himika Wasan1, K H Reeta2
1Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Abstract:
Despite achieving remarkable success in understanding the cellular, molecular and pathophysiological aspects of stroke, translation from preclinical research has always remained an area of debate. Although thousands of experimental compounds have been reported to be neuro-protective, their failures in clinical setting have left the researchers and stakeholders in doldrums. Though the failures described have been excruciating, they also give us a chance to refocus on the shortcomings. For better translational value, evidences from preclinical studies should be robust and reliable. Preclinical study design has a plethora of variables affecting the study outcome. Hence, this review focusses on the factors to be considered for a well-planned preclinical study while adhering to guidelines with emphasis on the study design, commonly used animal models, their limitations with special attention on various preventable attritions including comorbidities, aged animals, time of dosing, outcome measures and physiological variables along with the concept of multicentric preclinical randomized controlled trials. Here, we provide an overview of a panorama of practical aspects, which could be implemented, so that a well-defined preclinical study would result in a neuro-protectant with better translational value.
Insights
Translating preclinical stroke research to clinical success is challenging due to study design flaws. This review highlights key factors for robust preclinical studies to improve the development of effective neuroprotective agents.
Area of Science:
- Neuroscience
- Translational Medicine
- Pharmacology
Background:
- Despite advances in understanding stroke at cellular and molecular levels, translating preclinical findings into effective clinical treatments remains a significant challenge.
- Numerous neuroprotective compounds identified in preclinical studies have failed in clinical trials, necessitating a re-evaluation of research methodologies.
Purpose of the Study:
- To identify critical factors in preclinical study design that impact the translational value of neuroprotective agents for stroke.
- To provide practical recommendations for improving the robustness and reliability of preclinical stroke research.
Main Methods:
- Review of existing literature on preclinical stroke research and translational challenges.
- Emphasis on study design elements, animal models, and potential sources of attrition.
- Discussion of multicentric preclinical randomized controlled trials.
Main Results:
- Preclinical study outcomes are influenced by numerous variables including study design, animal model selection, comorbidities, animal age, dosing time, outcome measures, and physiological parameters.
- Preventable attritions in preclinical studies significantly hinder the development of successful neuroprotective therapies.
Conclusions:
- Implementing well-defined preclinical study designs, adhering to guidelines, and considering factors like multicentric trials can enhance the translational value of neuroprotective agents.
- A focus on robust and reliable preclinical evidence is crucial for advancing stroke treatment development.
Related Concept Videos
01:15Ischemic Stroke l: Introduction
01:15Ischemic Stroke ll: Pathophysiology
01:29Hemorrhagic Stroke ll: Pathophysiology